Device Trial Radar · NCT02903862
Health-eBrain Study
Last checked: Nov 20, 2026Latest source record: Jul 3, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Jul 2016
Primary completion
Jul 2017
Study completion Jul 2017
Sponsor
- Lead sponsor
- AnthroTronix, Inc.Not on our public-company list
- Sponsor type
- Industry
- Collaborators
- BrightFocus Foundation; Mindoula Health Inc.; 21st Century Brain Trust; Geoffrey Beene Foundation
- First posted
- Sep 16, 2016
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Model
- Parallel
- Masking
- None
- Primary purpose
- Supportive care
- Who can join
- All sexes, from 45 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purposes of this study are to (1) track dementia caregiver health indicators over 12 weeks, both with and without the Mindoula plus DANA intervention (case manager and mobile messaging and assessment applications) to determine if the intervention improves caregiver health and (2) obtain feedback from caregivers to inform on the design of future interventions.
Conditions
- Depression and Burden in Caregivers
Interventions
MindoulaBehavioral
The Mindoula intervention is a combination of case management and a messenger application. Case managers monitor how the participant is doing and any needs and provide 24/7 support \& assistance, including care coordination, treatment adherence, and matching the participant with providers and community resources. Each participant will be given an intake questionnaire to establish goals and behavioral health history. Participants will use the app and work with the case manager for 12 weeks.
DANADevice
DANA is an FDA-cleared neurocognitive assessment software administered on a smartphone or tablet to measure changes in cognitive efficiency. DANA also includes Ecological Momentary Assessments to track mood, sleep, stress, and memory. Intervention participants will take DANA weekly. The Waitlist Control arm will take DANA weekly 12 weeks after enrollment.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline M3 Behavioral Scale score over 12 weeksTime frame: At baseline, and 4, 8, and 12 weeks.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
AnthroTronix Inc
Silver Spring, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.